Related Experiment Video

Updated: Feb 22, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.4K

[Abnormal expression of RSK-4 and its clinical significance in breast cancer]

Jian-lun Liu1, Hua-wei Yang, Zu-shun Chen

  • 1Department of Breast Surgery, Cancer Hospital, Guangxi Medical University, Nanning 530021, China. jianlunliu@hotmail.com

Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]
|August 31, 2011
PubMed
Abstract

Insights

Down-regulation of ribosomal S6 kinase-4 (RSK-4) in breast cancer suggests it acts as a tumor suppressor gene. Reduced RSK-4 expression is linked to breast cancer development and progression.

Area of Science:

  • Molecular oncology
  • Gene expression analysis
  • Cancer biology

Context:

  • Breast cancer is a heterogeneous disease with complex molecular underpinnings.
  • Ribosomal S6 kinase-4 (RSK-4) is a kinase involved in cellular signaling pathways.
  • Understanding the role of specific genes like RSK-4 is crucial for advancing breast cancer research.

Purpose:

  • To investigate the expression levels of RSK-4 in breast cancer tissues compared to normal and benign breast tissues.
  • To determine the clinical significance of RSK-4 expression in relation to tumor characteristics.
  • To explore the potential role of RSK-4 as a tumor suppressor in breast cancer genesis and progression.

Summary:

  • RSK-4 mRNA and protein expression were significantly lower in breast cancer tissues than in normal or benign breast tissues.
  • Decreased RSK-4 expression correlated with larger tumor size, advanced clinical stage, and lymph node metastasis.
  • A significant correlation was observed between RSK-4 mRNA and protein expression levels.

Impact:

  • The findings suggest that RSK-4 acts as a tumor suppressor gene in breast cancer.
  • Down-regulation of RSK-4 is implicated in the development and progression of breast cancer.
  • RSK-4 may represent a potential therapeutic target or biomarker for breast cancer.

More Related Videos

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein07:08

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein

Published on: January 16, 2020

6.2K
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.5K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.8K